Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 15/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.39 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24418394 | 1.00 | MAP4K1 (0.49) | MAP4K1CDK2PRKCZFGFR1FGFR2 | |
| SCHEMBL24418818 | 0.92 | MAP4K1 (0.43) | MAP4K1 | |
| SCHEMBL28748452 | 0.92 | MAP4K1 (0.41) | MAP4K1 | |
| SCHEMBL29607829 | 0.90 | MAP4K1 (0.49) | MAP4K1CDK2PRKCZFGFR1FGFR2 | |
| SCHEMBL24418312 | 0.90 | MAP4K1 (0.49) | MAP4K1CDK2PRKCZFGFR1FGFR2 | |
| SCHEMBL24418389 | 0.89 | TNKS (0.44) | MAP4K1FGFR1FGFR2FGFR3BMPR1A | |
| SCHEMBL30596044 | 0.89 | TNKS (0.44) | MAP4K1FGFR1FGFR2FGFR3BMPR1A | |
| SCHEMBL24418318 | 0.88 | MAP4K1 (0.60) | MAP4K1 | |
| SCHEMBL29608016 | 0.88 | MAP4K1 (0.60) | MAP4K1 | |
| SCHEMBL24418439 | 0.88 | MAP4K1 (0.42) | MAP4K1FGFR1FGFR2FGFR3BMPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4223759-B1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BROADENBIO CO LTD (CN) | 2025-06-11 | — | — | EP | claimed |
| US-20230322789-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BROADENBIO CO., LTD. (CN) | 2023-10-12 | — | — | US | claimed |
| CN-114437074-A | Compound, pharmaceutical composition containing compound and application of compound | 北京伯汇生物技术有限公司 | 2022-05-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322789-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDXK, CMPK1, GCK | MAP4K1 156/4885CDK2 1239/4885PRKCZ 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.